NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

現實世界證據 (RWE) 解決方案市場 - 趨勢分析,競爭市場佔有率,預測:2016年∼2026年

Real-world evidence solution market, By value ; By Therapeutic Area ; By component ; By End User ; By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-2026.

出版商 Blueweave Consulting & Research Private Limited 商品編碼 986281
出版日期 內容資訊 英文 178 Pages
商品交期: 最快1-2個工作天內
價格
現實世界證據 (RWE) 解決方案市場 - 趨勢分析,競爭市場佔有率,預測:2016年∼2026年 Real-world evidence solution market, By value ; By Therapeutic Area ; By component ; By End User ; By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-2026.
出版日期: 2020年09月01日內容資訊: 英文 178 Pages
簡介

全球現實世界證據 (RWE) 解決方案市場,近幾年增加氣勢,預計至2026年達到33億2,170萬美元,2020年∼2026年以16.5%的年複合成長率成長。

本報告提供全球現實世界證據 (RWE) 解決方案市場調查分析,市場概要,各地區的市場規模與預測,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 調查架構

第2章 調查手法

第3章 摘要整理

第4章 全球現實世界證據 (RWE) 解決方案產業考察

  • DROC分析
    • 成長促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 技術形勢/最近的開發
  • 波特的五力分析
  • 法律規範

第5章 全球現實世界證據 (RWE) 解決方案市場概要

  • 市場規模與預測:各金額
    • 各金額
  • 市場佔有率與預測
    • 各治療領域
      • 心血管
      • 腫瘤
      • 免疫
      • 其他
    • 各零件
      • 資料集
      • 服務
    • 各終端用戶
      • 醫療設備
      • 保險者
      • 製藥
      • 提供者
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美的現實世界證據 (RWE) 解決方案市場

  • 市場規模與預測:各金額
    • 各金額
  • 市場佔有率與預測
    • 各治療領域
    • 各零件
    • 各終端用戶
    • 各國
      • 美國
      • 加拿大

第7章 歐洲的現實世界證據 (RWE) 解決方案市場

  • 市場規模與預測:各金額
    • 各金額
  • 市場佔有率與預測
    • 各治療領域
    • 各零件
    • 各終端用戶
    • 各國
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他的歐洲

第8章 亞太地區的現實世界證據 (RWE) 解決方案市場

  • 市場規模與預測:各金額
    • 各金額
  • 市場佔有率與預測
    • 各治療領域
    • 各零件
    • 各終端用戶
    • 各國
      • 中國
      • 印度
      • 日本
      • 其他的亞太地區

第9章 南美的現實世界證據 (RWE) 解決方案市場

  • 市場規模與預測:各金額
    • 各金額
  • 市場佔有率與預測
    • 各治療領域
    • 各零件
    • 各終端用戶
    • 各國
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他南美

第10章 中東、非洲的現實世界證據 (RWE) 解決方案市場

  • 市場規模與預測:各金額
    • 各金額
  • 市場佔有率與預測
    • 各治療領域
    • 各零件
    • 各終端用戶
    • 各國
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 南非
      • 其他中東、非洲

第11章 競爭情形

  • 企業的市場佔有率/排行榜分析

第12章 產業整體中COVID-19的影響

第13章 企業簡介

  • Anthem, Inc.
  • Clinigen Group plc
  • Cognizant Technology Solutions Corporation
  • International Business Machines (IBM) Corporation
  • ICON Public Limited
  • Quintiles IMS Holdings, Inc.
  • UnitedHealth Group
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • 其他主要企業
目錄
Product Code: bwc20155

Title:
Real-world evidence solution market, By value (Market share and forecast); By Therapeutic Area (cardiovascular, oncology, immunology, others); By component (Dataset, Clinical setting data, Claims data, Pharmacy Data, Patient-Powered Data); By End User (Medical Devices, Players, Pharmaceuticals, Providers); By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-2026..

Global Real-World Evidence Solutions market has gained momentum in recent years with a CAGR of 16.5%, in value terms, over the forecast period 2020-2026, and is expected to reach USD 3,321.7 million by 2026. The growth is due to the shift from volume to value-based care, increasing aging population and prevalence of chronic diseases and delays in drug development, and the subsequent increase in development costs. Besides, the real-world data sets are widely adopted by end-users for RWE for various applications such as drug development & approvals, market access & reimbursement/coverage decisions, clinical decision-making, and medical device development & approvals, among others, that helps in the growth of the overall market.

Therapeutic segment contributing major share to drive the real-world evidence solution market.

Based on the therapeutic area, the real-world evidence market is broadly categorized into oncology, immunology, neurology, cardiovascular disease, and other therapeutic areas the oncology segment has been accounted for the largest share of the real-world evidence market. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide. According to the World Health Organization (WHO), Cancer is the second leading cause of death across the globe, with an estimated 9.6 million deaths in 2018. There is also an increasing personalized medicine and a more precise requirement for oncology, which is expected to further fuel the market growth.

Rising in the investment market to create market opportunities in upcoming years.

A rise in investment creates new opportunities in the market. For instance, Syapse, a San Francisco, CA-based provider of precision oncology solutions announced USD 30 million in new equity funding to accelerate the creation and use of real-world evidence (RWE) in oncology led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital. Revelation Alpine's Managing Partner Zack Scott, MD will join the Syapse Board of Directors. Syapse collaborates with life sciences companies to provide insights from real-world data through its portfolio of products to support research and product development, clinical trials patient matching, real-world evidence regulatory filings, and monitoring of commercially approved products. Syapse supports health systems with insights to support health systems' large-scale precision medicine programs through integrating the clinical, molecular, and outcomes data they need to make the most informed treatment decisions.

North America real-world evident solution market size and forecast

North America accounted for the largest share of the real-world evidence market in 2019, followed by Europe and the Asia Pacific. The presence of a favorable regulatory environment, a high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real-world evidence market. The US is expected to dominate the North American market, owing to a high demand in clinical research activities, which is one of the important factors augmenting the demand for real-world evidence solutions market in the North America region.

Creativity tool product: Competitive Landscape

Key players for Real World Evidence Solutions Market: Anthem, Inc., Clinigen Group plc, Cognizant Technology Solutions Corporation, International Business Machines (IBM) Corporation, ICON Public Limited, Quintiles IMS Holdings, Inc., UnitedHealth Group, Oracle Corporation, PAREXEL International Corporation, PerkinElmer, Inc., and other Prominent Players.

Anthem - The company offers and generates consistent and actionable evidence to support decision making while helping to guide fresh initiatives for a range of stakeholders in the healthcare industry through wholly-owned health outcomes research subsidiary, HealthCore, Inc. HealthCore, Inc. operates through three divisions namely, life science companies, government & academia, and payers & providers.

Table of Contents

1.Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Research
  • 2.2. Quantitative Research
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Primary & Secondary Research
    • 2.3.2. Secondary Research
    • 2.3.3. Primary Research
  • 2.4. Breakdown of Primary Research Respondents, By Region
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Real World Evidence Solution Industry Insights

  • 4.1. DROC Analysis
    • 4.1.1. Growth Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. Technological Landscape/Recent Development
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Intensity of Rivalry
  • 4.4. Regulatory Framework

5. Global Real World Evidence Solution Market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area
      • 5.2.1.1. Cardiovascular
      • 5.2.1.2. Oncology
      • 5.2.1.3. Immunology
      • 5.2.1.4. Others
    • 5.2.2. By Component
      • 5.2.2.1. Dataset
      • 5.2.2.1.1. Clinical Setting Data
      • 5.2.2.1.2. Claims Data
      • 5.2.2.1.3. Pharmacy
      • 5.2.2.1.4. Patient Powered Data
      • 5.2.2.2. Services
    • 5.2.3. By End User
      • 5.2.3.1. Medical Devices
      • 5.2.3.2. Payers
      • 5.2.3.3. Pharmaceuticals
      • 5.2.3.4. Providers
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia Pacific
      • 5.2.4.4. Latin America
      • 5.2.4.5. Middle East & Africa

6. North America Real World Evidence Solution Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By Component
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. United States
      • 6.2.4.2. Canada

7. Europe Real World Evidence Solution Market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By Component
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. Germany
      • 7.2.4.2. United Kingdom
      • 7.2.4.3. France
      • 7.2.4.4. Italy
      • 7.2.4.5. Spain
      • 7.2.4.6. Rest of Europe

8. Asia Pacific Real World Evidence Solution Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By Component
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. China
      • 8.2.4.2. India
      • 8.2.4.3. Japan
      • 8.2.4.4. Rest of Asia Pacific

9. Latin America Real World Evidence Solution Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By Component
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Brazil
      • 9.2.4.2. Mexico
      • 9.2.4.3. Argentina
      • 9.2.4.4. Rest of Latin America

10. Middle East & Africa Real World Evidence Solution Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By Component
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. Saudi Arabia
      • 10.2.4.2. UAE
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1.Company market share/Ranking Analysis 2019

12. Impact of COVID-19 across Industry

13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 13.1.Anthem, Inc.
  • 13.2.Clinigen Group plc
  • 13.3.Cognizant Technology Solutions Corporation
  • 13.4.International Business Machines (IBM) Corporation
  • 13.5.ICON Public Limited
  • 13.6.Quintiles IMS Holdings, Inc.
  • 13.7.UnitedHealth Group
  • 13.8.Oracle Corporation
  • 13.9.PAREXEL International Corporation
  • 13.10. PerkinElmer, Inc.
  • 13.11. Other Prominent Players